Hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) can affect many parts of the body. Nerve symptoms are often the earliest signs of this condition. hATTR-PN is a rare genetic ...
Inflammation that lasts a long time CIDP (cerebral demyelinating polyneuropathy) is an uncommon neurological condition that results in paralysis (impairment of sensory function in limbs). The ...
This week we are going to discuss briefly a presentation of peripheral neuropathy. Peripheral neuropathy occurs for many, many reasons. One of the primary causes is diabetes mellitus both types 1 and ...
CARLSBAD, Calif., Dec. 21, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved Ionis and AstraZeneca's ...
Hereditary transthyretin-mediated amyloidosis (hATTR) is a type of amyloidosis, which is a group of diseases where abnormal proteins (amyloids) build up and damage areas of the body. When the amyloids ...
The FDA has approved Amvuttra, an RNA interference therapeutic for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. Amvuttra (vutrisiran, Alnylam ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has granted ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Ionis’ WAINUA™ (eplontersen) has been approved in the US for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback